Auxora, the i.v. formulation of the Orai1 selective blocker zegocractin (CM4620) has been tested in several clinical trials (Phase I/II) including studies targeting patients with acute pancreatitis or COVID-19 pneumonia (19, 32). This evidence concerns the gene ORAI1 and acute pancreatitis.